Blood cancer protein may predict patient outcomes

NCT ID NCT04546945

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at a protein called CD56 in people with blood cancers like multiple myeloma and leukemia. Researchers want to see how common CD56 is and whether it is linked to how well patients do. The study will include 38 newly diagnosed patients and use a lab test called flow cytometry to measure CD56.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors use CD56 levels to better predict how blood cancers will progress.

What could go wrong

This is a small, early observational study, not a treatment trial. It may not find a clear link between CD56 and patient outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Assiut University

    COMPLETED

    Asyut, Egypt

  • Assiut university

    RECRUITING

    Asyut, Egypt

    Contact